Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ABBVIE LIMITED,Upadacitinib,"Psoriatic arthritis (PsA), 3rd line biologic",Upadacitinib (RINVOQÂ®),Options for investment,Community,Oncology Agents and Immunosuppressants
